Overview

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Status:
Completed

Trial end date:
2015-12-31

Target enrollment:

Participant gender:

Summary

This trial is conducted in Europe. The aim of this trial is to compare NNC0123-0000-0338 (insulin-338) in a tablet formulation and insulin glargine in combination with metformin with or without DPP-4 inhibitor in subjects with type 2 diabetes currently treated with oral antidiabetic therapy

Phase:

Phase 2

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Hypoglycemic Agents
Insulin
Insulin Glargine
Insulin, Globin Zinc